The Origin Investigation

Parts I through IV of The Geneva Files documented the man, the moment, the money, and the instruments — the selection of Director-General Tedros Adhanom Ghebreyesus, the institutional posture of the World Health Organization during the early pandemic, the funding architecture that constrains the institution's independence, and the legal instruments through which the institution exercises authority. Part V documents the place where all four threads converge: the investigation into the origin of the pandemic itself. When the question of where SARS-CoV-2 came from needed answering, the World Health Organization was the institution the world looked to. This Part documents the two investigations the WHO conducted, the conflicts and constraints that shaped them, and the conclusion that the documentary record establishes — not about where the virus came from, which remains, on the WHO's own 2025 admission, unresolved, but about whether the institution was structurally capable of finding out.

This Part examines the WHO's two origin investigations through the public documentary record. Its focus is the institutional constraints, the access terms, the team composition, and the data availability that shaped what those investigations could and could not conclude. It does not determine the origin of SARS-CoV-2, which the WHO's own later assessments have left unresolved. The structural finding of this Part is not a claim about the origin of the virus. It is a claim about the investigation. The documentary record establishes that the WHO conducted its origin inquiry as a joint study on terms negotiated with the government of the country at the center of the inquiry; that the team included a member with a documented and, at the time, undisclosed professional relationship to the specific laboratory at the center of one hypothesis; that the team's central conclusion on that hypothesis was publicly questioned by the WHO's own Director-General within days of its announcement; that the team did not receive the raw data it had requested; that the mission's own lead later stated the team had been pressured to drop a hypothesis; and that a second, larger WHO investigation, launched in response to the criticism of the first, closed more than four years later without reaching a conclusion — because, the Director-General stated plainly, data the host government held was never provided. The origin of the pandemic remains officially unresolved. The constraints that left it unresolved are the subject of this Part.

The Part proceeds through nine sections. Section I documents the question and the terms on which the investigation was conducted. Section II documents the four-week mission of January and February 2021. Section III documents the report and the Director-General's response to it. Section IV documents the conflict of interest at the center of the team. Section V documents the data that was never shared. Section VI documents the second investigation and its dead end. Section VII documents the divergence between the WHO's conclusion and the assessments of the United States intelligence community. Section VIII catalogs the pattern across the five parts of this series. Section IX is the discipline section that closes every part of this series.

The Question and the Terms

The demand for an origin investigation was formal and early. In May 2020, the World Health Assembly — the governing body of the WHO, comprising all member states — adopted a resolution calling on the WHO to identify the zoonotic source of the virus and the route of its introduction into the human population. The resolution was the institutional mandate for what became the origin investigation. The mandate was clear. The terms on which it would be carried out were not yet settled, and the settling of those terms is the first structural feature of the investigation that the documentary record establishes.

An advance team of two WHO experts traveled to China in July 2020 to develop the scope and terms of reference for the international mission. The terms of reference that emerged from that process were not set by the WHO unilaterally. They were negotiated with the Chinese government. The investigation that resulted was not, in its formal structure, an independent WHO inquiry into the origin of the pandemic. It was a joint study — a collaboration between the WHO's international experts and a Chinese scientific team, conducted under terms to which the Chinese government had agreed, on Chinese territory, with Chinese authorities controlling access to sites, samples, and data.

The distinction between an independent investigation and a joint study is not a technicality. It is the structural fact that shaped everything that followed. In an independent investigation, the investigating body determines what it will examine, what evidence it will demand, and what conclusions the evidence supports. In a joint study conducted on the territory and under the terms of the investigated party, the investigating body examines what it is permitted to examine, receives the evidence it is given, and reaches conclusions within the constraints of that access. The WHO origin investigation was the second kind. It was, from its inception, an inquiry whose scope was shaped by the party whose conduct was, in part, the subject of the inquiry.

The international team that arrived in Wuhan in mid-January 2021 comprised experts from ten countries — a team of roughly a dozen international scientists, working alongside a Chinese counterpart team. The mission was scheduled for four weeks. Its composition, its itinerary, and the data it would be shown had all been shaped by the negotiated terms of reference. The team did not arrive with the authority to compel the production of evidence. It arrived with the access that had been agreed to in advance.

The Mission

The four-week mission ran from mid-January to mid-February 2021. The team visited the sites that had become central to the origin question: the Huanan Seafood Wholesale Market, where a substantial cluster of early cases had been identified; the Wuhan Center for Disease Control; and the Wuhan Institute of Virology, the laboratory that had, for years, conducted research on bat coronaviruses and that sat at the center of the hypothesis that the pandemic might have begun with a laboratory incident.

The mission organized its inquiry around four hypotheses for how the virus had entered the human population. The first was direct zoonotic spillover — transmission directly from an animal reservoir, such as a bat, to humans. The second was transmission through an intermediate host species — from a reservoir animal to a second animal and then to humans. The third was transmission through the cold chain — the frozen-food supply chain, a hypothesis actively promoted by Chinese state media that would locate the virus's introduction outside China. The fourth was a laboratory-associated incident — the escape of the virus from a research facility.

It should be said at the outset that there was a genuine scientific basis for the early focus on the zoonotic pathways. A substantial cluster of the earliest known cases was associated with the Huanan Seafood Wholesale Market, where live animals were sold; the region's research community had documented the circulation of bat coronaviruses; and the two most recent comparable coronavirus outbreaks, SARS in 2002 and MERS in 2012, had both originated in animal-to-human spillover. For many scientists, zoonotic transmission was the natural primary hypothesis on the evidence available at the time, and the mission's emphasis on it was not, in itself, evidence of anything improper. What the documentary record raises is not the attention paid to the zoonotic pathways but the asymmetric treatment of the laboratory pathway relative to the others.

On February 9, 2021, at a joint press conference in Wuhan with Chinese officials, the mission's lead, the WHO food-safety scientist Peter Ben Embarek, announced the team's initial findings. The most likely pathway, he said, was introduction through an intermediate host species, a pathway requiring further study. And on the fourth hypothesis, the announcement was definitive in a way the others were not. The laboratory-incident hypothesis, Ben Embarek said, was "extremely unlikely" — and, he added, it would not be suggested as an avenue of future study.

The asymmetry in that announcement is the documentary detail that matters. Three of the four hypotheses — direct zoonotic, intermediate host, and cold chain — were kept open for further investigation. Only one was closed. The hypothesis that was closed was the one that implicated the conduct of the host government's own laboratory. The hypothesis that was actively kept open included the cold-chain theory that the host government's own media had been promoting. The investigation's framing, at the moment of its first public conclusion, tracked the preferences of the party on whose territory and under whose terms it had been conducted.

The Report and the Director-General's Response

The joint WHO-China study report was released on March 30, 2021. It ran to several hundred pages and provided detailed reasoning for the team's conclusions. It ranked the four hypotheses on a scale of likelihood. Transmission through an intermediate host was assessed as "likely to very likely." Direct zoonotic spillover was assessed as "possible to likely." The cold-chain pathway was assessed as "possible." And the laboratory-incident hypothesis was assessed as "extremely unlikely." The report proposed further research in every area — except the laboratory hypothesis, which it recommended against pursuing.

What happened next is the documented sequence that gives this Part its center of gravity. On the same day the report was released, the Director-General of the World Health Organization — Tedros Adhanom Ghebreyesus, the head of the institution that had co-conducted the investigation — publicly stated that he did not believe the assessment of the laboratory hypothesis had been extensive enough. He stated that further data and studies would be needed to reach more robust conclusions, and that, in his words, all hypotheses remained "on the table."

I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions. All hypotheses remain on the table. Tedros Adhanom Ghebreyesus — WHO Director-General, March 30, 2021

The significance of the statement lies in its source. It was not an outside critic questioning the WHO's findings. It was the head of the WHO, on the day the joint study was published, stating publicly that the study had not adequately examined one of the four hypotheses it had assessed — the one it had ranked least likely. For the Director-General of the institution that produced an investigation to state, on the day of its release, that its treatment of a central question had not been extensive enough is an unusual public posture toward one's own organization's flagship work. It is, at a minimum, a documented indication that the adequacy of the laboratory assessment was contested within the WHO's own leadership.

On the day the joint study was published, the WHO's own Director-General stated that its assessment of the laboratory hypothesis had not been extensive enough.

Tedros returned to the point in the months that followed. In July 2021, he stated that it had been "premature" to rule out the laboratory hypothesis, and offered a personal observation: that he had himself worked as a laboratory technician, that laboratory accidents happen, and that the hypothesis therefore could not responsibly be set aside. By mid-2021, the Director-General was publicly maintaining a position at odds with the central finding on the laboratory question in the investigation his own organization had co-authored with the Chinese government four months earlier.

The Conflict at the Center

The structural problem with the investigation was not only the terms on which it was conducted. It was also the composition of the team that conducted it. And the documentary record on that point centers on a single member.

Peter Daszak is a British zoologist and the president of EcoHealth Alliance, a New York-based research organization. He was the only American-based member of the WHO international team. He was also, by the time he joined that team, the Western scientist with arguably the deepest documented professional relationship to the specific laboratory at the center of the laboratory-incident hypothesis — the Wuhan Institute of Virology.

The relationship is documented in the federal record. As detailed in Part II of the companion Fauci Files series, EcoHealth Alliance, under Daszak's leadership, served as the intermediary that channeled United States National Institutes of Health grant funding to the Wuhan Institute of Virology. Between 2014 and 2019, EcoHealth directed approximately $600,000 of NIH grant funding to the WIV for research on bat coronaviruses. Daszak co-authored approximately a dozen scientific papers with the WIV's lead coronavirus researcher, Shi Zhengli. He had spent years as the WIV's most prominent Western collaborator on precisely the category of research — bat coronavirus research — that the laboratory-incident hypothesis concerned.

The conflict went beyond the funding relationship. In February 2020, before he joined the WHO team, Daszak organized a statement published in the medical journal The Lancet, signed by a group of scientists, that branded the suggestion of a laboratory origin a "conspiracy theory." The statement did not disclose Daszak's own funding and collaboration ties to the WIV — the very laboratory whose potential involvement the statement was dismissing. Daszak, in other words, had publicly and influentially worked to discredit the laboratory hypothesis, without disclosing his relationship to the laboratory, before he was placed on the international team responsible for investigating that same hypothesis.

The WHO was aware of the concern. Daszak provided the WHO with a conflict-of-interest statement, and the WHO accepted him onto the team. He participated in the team's examination of the Wuhan Institute of Virology — the institution he had funded and collaborated with for years — and in the team's conclusion that a laboratory incident was "extremely unlikely."

The subsequent congressional record sharpened the picture. The House Select Subcommittee on the Coronavirus Pandemic, in its 2024 investigation, found that Daszak had misled federal agencies about EcoHealth's relationship with the WIV and concluded that he had, in the subcommittee's language, omitted a material fact regarding his access to unanalyzed virus samples and sequences at the WIV in the course of securing the reinstatement of an NIH grant. In May 2024, the Department of Health and Human Services suspended all of EcoHealth Alliance's federal funding and moved to formally debar the organization and Daszak from receiving federal funds. The subcommittee recommended a criminal investigation.

None of this establishes that Daszak engineered the WHO team's conclusion, and this Part does not assert that he did. He was one member of a team of roughly a dozen international experts working alongside a Chinese counterpart team, and the joint study's conclusions, including the "extremely unlikely" characterization of the laboratory hypothesis, emerged from that joint, consensus-oriented process rather than from any single member. There is no evidence in the public record that Daszak dictated the outcome, and it would be wrong to suggest otherwise. What the documentary record establishes is narrower and rests on appearance and disclosure rather than on any individual's decisive influence: the international inquiry that examined the Wuhan Institute of Virology included, as its only U.S.-based member, the person who had spent the preceding years funding and collaborating with that laboratory, and who had already publicly characterized the hypothesis under examination as a conspiracy theory without disclosing his ties to its subject. The WHO accepted him onto the team after he furnished a conflict-of-interest statement. An investigation so composed carries an appearance-of-bias problem that the WHO acknowledged the existence of, addressed through disclosure, and proceeded past — and readers can weigh for themselves what that arrangement does to the independence of the result.

The Data That Was Never Shared

The deepest structural failure of the investigation was neither its terms nor its composition. It was the evidence the team was never given. An origin investigation depends, above all, on access to the primary data of the early outbreak — the raw, line-level records of the first known cases, the samples, the laboratory records, the genetic sequences. The WHO team did not receive that data. It received, in substantial part, summary analyses prepared by its Chinese counterparts rather than the underlying records themselves.

The specific categories of primary data that were not made available to the team are documented. They included the detailed line-level epidemiological records of the earliest known cases from December 2019; the full genomic sequences, with their associated patient metadata, from those early patients; the comprehensive results of animal sampling conducted at the Huanan market and across its related supply chains; and the laboratory records and database contents of the Wuhan Institute of Virology — including the contents of a WIV sample-and-sequence database that had been taken offline in late 2019 and was never restored to outside view. These are not peripheral records. They are the precise categories of evidence on which any rigorous determination of the virus's origin would depend. Their absence is the reason the determination could not be made.

The team's lead later acknowledged the constraint in terms that went beyond the absence of data to the presence of pressure. In an August 2021 interview, Peter Ben Embarek — the same scientist who had announced the "extremely unlikely" conclusion in Wuhan — acknowledged that the team's Chinese counterparts had pressured the international experts to drop the laboratory hypothesis from the report. The conclusion that the laboratory incident was "extremely unlikely," in other words, was reached not through the free evaluation of complete evidence but, by the mission lead's own later account, under pressure from the host government and without the primary data that a genuine evaluation would have required.

This is the point at which the structural argument of the entire Geneva Files series comes into focus. Part II documented the WHO's institutional posture of accommodation toward the Chinese government during the early pandemic. Part III documented the funding architecture that constrains the WHO's independence. Part V documents how those structural features bore on the single most consequential investigation the WHO has conducted in a generation. An intergovernmental institution dependent on the cooperation of its member states, lacking any authority to compel the production of evidence, was asked to investigate a question that turned on evidence held within the territory of one of its most powerful members. It conducted the inquiry as a joint study on terms negotiated in advance, with a team that included a member with a documented conflict, did not receive the primary data, and — by the mission lead's own later account — was pressured to set aside one hypothesis. The limitations on access, data, and hypothesis treatment that the documentary record describes are consistent with the constraints that any joint study would face when it is conducted under terms negotiated with the government whose institutions and territory are central to the inquiry. They are the predictable limits of an investigative body that has no power to compel, not evidence of a predetermined design. That distinction matters: the case this series makes is about institutional structure and incentives, not about a coordinated plot.

The Do-Over and the Dead End

The criticism of the 2021 joint study was substantial and came from within the scientific community as much as from outside it. In response, the WHO established a second body: the Scientific Advisory Group for the Origins of Novel Pathogens — SAGO — a group of twenty-seven international experts convened in late 2021 to conduct a more rigorous and independent assessment of the origin question. SAGO was the institutional acknowledgment that the first investigation had not been adequate. It was the do-over.

SAGO worked for more than three years. It released initial findings in 2022 and continued its assessment through subsequent years. On June 27, 2025, it published its conclusion. The conclusion was that there was no conclusion. SAGO determined that, on the evidence available, zoonotic spillover remained the best-supported hypothesis — but that the origin of the pandemic could not be established, and that the laboratory hypothesis could neither be confirmed nor excluded. The reason, the SAGO chair stated plainly, was that the information required to investigate it had never been made available.

It is important to be precise about the symmetry of the uncertainty, because the inconclusiveness runs in both directions. The natural-origin hypotheses are also unproven. After more than five years, no intermediate host species has been identified — no animal has been found carrying a virus close enough to SARS-CoV-2 to establish the spillover chain — and direct zoonotic transmission from bats has not been confirmed with the epidemiological or genomic links that such a finding would require. The concentration of early cases around the Huanan market is a genuine and significant evidentiary signal, and it is the principal basis for SAGO's assessment that spillover remains the best-supported hypothesis on the available data. But a best-supported hypothesis is not a proven one. The absence of an identified intermediate host is part of why SAGO described the overall picture as inconclusive even while favoring the zoonotic explanation. This Part does not assert a laboratory origin; it equally does not assert that the zoonotic question is closed. Both remain open, and the reason both remain open is the same: the primary evidence that would resolve them was never made available.

Until further requests for information are met, or more scientific data becomes available, the origins of SARS-CoV-2 and how it entered the human population will remain inconclusive. Marietjie Venter — SAGO Chair, June 27, 2025

The SAGO chair stated that the laboratory hypothesis "could not be investigated or excluded" because much of the needed information had not been made available, and that requests for unpublished information from other countries had also gone unmet. The internal strain on the body was visible in its final days: one SAGO member resigned, and three others asked for their names to be removed from the report.

The Director-General's accompanying statement was the most direct acknowledgment the WHO has made of the structural failure this Part documents. Tedros stated that, despite repeated requests, China had not provided hundreds of viral sequences from individuals infected early in the pandemic, had not provided more detailed information on the animals sold at the Wuhan markets, and had not provided information on the work done and the biosafety conditions at the Wuhan laboratories. He stated that the WHO had also requested access to the intelligence reports of national governments and had not received them. And he concluded, more than five years after the pandemic began and after two full WHO investigations, that all hypotheses remained on the table.

Despite our repeated requests, China hasn't provided hundreds of viral sequences from individuals with COVID-19 early in the pandemic. As things stand, all hypotheses must remain on the table. Tedros Adhanom Ghebreyesus — WHO Director-General, June 27, 2025

The do-over reached the same wall as the original. Two investigations, more than four years apart, both defeated by the same absence: the data held by the government on whose territory the pandemic began, and on whose cooperation the WHO had no means to insist.

The Divergence

While the WHO's two investigations were reaching their inconclusive end, the national intelligence services of the United States were reaching assessments of their own — and those assessments diverged sharply from the "extremely unlikely" conclusion of the 2021 joint study.

The divergence is documented in the public record of the United States intelligence community's assessments. The Federal Bureau of Investigation assessed, with moderate confidence, that the pandemic most likely originated from a laboratory incident. The Department of Energy assessed, with low confidence, that a laboratory origin was most likely. In January 2025, the Central Intelligence Agency assessed that a laboratory origin was more likely than a natural one, albeit with low confidence. Other elements of the intelligence community assessed natural origin as more likely, and the community as a whole did not reach consensus. These assessments were reached with access to different sources than the WHO scientific team — intelligence channels rather than site visits and scientific data — and they carry their own limitations; the confidence levels attached to them were, in most cases, low, and the community did not converge on a single answer. The point relevant to this Part is not which assessment is correct. It is that multiple agencies of the United States government, examining the same question, reached conclusions ranging from divided to favoring a laboratory origin with varying levels of confidence — a markedly different distribution of judgment than the "extremely unlikely" conclusion the WHO joint study had announced in Wuhan in 2021.

The divergence is itself a piece of evidence — not about the origin of the virus, but about the nature of the WHO investigation. The WHO mission and the U.S. intelligence agencies were drawing on different information channels: the mission had negotiated scientific and diplomatic access and, in substantial part, summary analyses rather than raw line-level early-case and sequence data; the intelligence agencies had their own sources, which the WHO did not see, and which remained divided among themselves. Independent entities working from different evidence reached different weightings of the same question. That is not, in itself, proof that either was right or that the WHO was captured. It is an illustration of how much an investigation's conclusion depends on the evidence it can actually obtain — and the WHO mission, by the documented constraints on its access, could obtain less than a full evaluation of the question required. The gap between the WHO's "extremely unlikely" and the divided, lab-leaning judgments of some U.S. agencies is, on this reading, a measure of the difference in access rather than a verdict on the origin.

The full reckoning with the accountability questions this divergence raises — the questions of what was known, when, and by whom, and of what the institutional and individual consequences should be — is the subject of Part VI, the final part of this series. Part V establishes only the documented fact of the divergence and its significance as a measure of the WHO investigation's constraints.

The Pattern Across Five Parts

Read together, Parts I through V of The Geneva Files document the institutional architecture of the World Health Organization and the single investigation in which every structural feature of that architecture was tested at once.

Part I documented the selection of a Director-General whose path to office ran through contested practices as a national health minister and the diplomatic support of the Chinese government.

Part II documented the WHO's posture of accommodation toward the Chinese government during the early pandemic — the deference, the praise, the delay — that the Independent Panel characterized as reflecting an evident desire to maintain good relations.

Part III documented the funding architecture — the shift to donor-directed voluntary contributions — that constrains the institution's independence.

Part IV documented the legal instruments through which the institution exercises authority over member states, and the mechanisms through which it influenced American health policy without formal authority.

Part V has documented the origin investigation — the inquiry in which the institutional features the earlier parts described, the negotiated access, the funding-driven dependence, and the limits on the WHO's authority, all bore on a single question at once, and produced two investigations that reached the same data-access wall.

The pattern is consistent and, by the end of the series, difficult to overlook. An intergovernmental institution dependent on the cooperation of the member states it works alongside is poorly positioned to scrutinize a powerful member state that declines to cooperate. The origin investigation illustrates the pattern. The WHO was asked to examine a question that turned on evidence held on the Chinese government's territory, and it had neither the authority to compel that evidence nor the means to proceed without it. It conducted the inquiry it was permitted to conduct, reached the conclusions that inquiry permitted, and saw its own Director-General publicly question the adequacy of the central one within hours. Four years later, after a second attempt, the WHO stated that it still could not determine how the pandemic began.

The final part of this series, Part VI — The Reckoning — will draw together the structural findings of all six parts and examine the question they collectively raise: what an institution with the WHO's documented dependencies, conflicts, and constraints can legitimately be trusted to do, and what the architecture of global health governance would need to become for the failures this series has documented not to recur.

What This Part Establishes

This Part has documented an investigation. It has not, deliberately, made certain claims that the documentary record does not support.

It has not established that COVID-19 originated in a laboratory. The origin of the pandemic remains, on the WHO's own June 2025 admission, unresolved. The documentary record this Part has assembled does not establish a laboratory origin, and this Part does not assert one. What it establishes is that the investigation conducted to answer the question was structurally incapable of answering it.

It has not established that the zoonotic-spillover hypothesis is wrong. SAGO's 2025 assessment that zoonotic spillover remains the best-supported hypothesis on the available evidence is a serious scientific judgment, and the concentration of early cases around the Huanan market is a genuine evidentiary fact that the zoonotic hypothesis accounts for. The structural concern this Part documents is not that the zoonotic hypothesis is false, but that the investigation could not reach a confident conclusion because the primary data was withheld.

It has not established that Peter Daszak, or any other individual member of the WHO team, acted in bad faith or engineered the investigation's conclusion. The documentary record establishes a structural conflict of interest — the placement, on a team investigating a laboratory, of that laboratory's most prominent Western funder and collaborator, who had already publicly dismissed the hypothesis under investigation. The structural conflict is sufficient to compromise the appearance and substance of independence without any finding of individual bad faith, and this Part asserts no such finding.

What this Part does establish is that the World Health Organization conducted its origin investigation as a joint study on terms negotiated with the government whose territory and institutions were central to the inquiry; that the team included a member with a documented and, at the time, undisclosed relationship to the laboratory at the center of one hypothesis; that the team characterized a laboratory incident as "extremely unlikely" while keeping every other hypothesis open, including the cold-chain theory the host government promoted; that the WHO's own Director-General publicly stated, the day the report was published, that the laboratory assessment had not been extensive enough, and called it "premature" within months; that the mission lead later stated the team had been pressured to set aside the laboratory hypothesis; that the team did not receive the primary data of the early outbreak; that a second WHO investigation, convened in response to the criticism of the first, closed in June 2025 without a conclusion; that the Director-General attributed that outcome to data the Chinese government did not provide; and that the WHO's characterization diverged from the divided, partly lab-leaning assessments later reached by United States intelligence agencies drawing on different evidence. The origin of the pandemic remains unresolved. The documentary record indicates that the constraints on the investigations — negotiated access, the absence of any power to compel evidence, and the data the host government did not provide — are sufficient to account for why it remains unresolved.

The documentary record speaks. The world asked the World Health Organization to find out where the pandemic began. The institution conducted two investigations across more than four years and, by the admission of its own Director-General, could not find out — because the evidence lay inside the borders of a member state that did not provide it, and the WHO had no means to insist. That outcome is less a failure of science than a limit of institutional design: an intergovernmental body investigating a member state can reach only as far as that state's cooperation allows. The next and final part of this series examines what that limit demands — of the WHO, and of the architecture of global health governance built around it.